Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 21;31(11):1986-2001.e9.
doi: 10.1016/j.chembiol.2024.09.010. Epub 2024 Oct 24.

The liquid lectin array detects compositional glycocalyx differences using multivalent DNA-encoded lectins on phage

Affiliations

The liquid lectin array detects compositional glycocalyx differences using multivalent DNA-encoded lectins on phage

Guilherme M Lima et al. Cell Chem Biol. .

Abstract

Selective detection of disease-associated changes in the glycocalyx is an emerging field in modern targeted therapies. Detecting minor glycan changes on the cell surface is a challenge exacerbated by the lack of correspondence between cellular DNA/RNA and glycan structures. We demonstrate that multivalent displays of lectins on DNA-barcoded phages-liquid lectin array (LiLA)-detect subtle differences in density of glycans on cells. LiLA constructs displaying 73 copies of diCBM40 (CBM) lectin per virion (φ-CBM73) exhibit non-linear ON/OFF-like recognition of sialoglycans on the surface of normal and cancer cells. A high-valency φ-CBM290 display, or soluble CBM protein, cannot amplify the subtle differences detected by φ-CBM73. Similarly, multivalent displays of CBM and Siglec-7 detect differences in the glycocalyx between stem-like and non-stem populations in cancer. Multivalent display of lectins offer in situ detection of minor differences in glycocalyx in cells both in vitro and in vivo not feasible to currently available technologies.

Keywords: DNA barcoding; LiLA; cell surface; glycan-binding proteins; glycocalyx; lectin array; multivalency; phage; profiling.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests R.D. is shareholder of the start-up company 48Hour Discovery Inc. that licensed the patent application (WO2018141058A1) describing LiGA technology.

LinkOut - more resources